房颤患病人群基数庞大，受人口老龄化加剧影响， 预计到2025年，房颤患病人数将达到2266.6万人 ，2021- 2025年的复合年增长率为2.85%，手术需求较高。 在心脏消融领域，包括" 冰 "、" 火 "、" 电 "三种消融能量类型的心脏电生理解决方案——"火元素" 射频消融 、"冰元素" 冷冻消融 及"电元素" 脉冲电场消融（PFA） 。 招商通知 第三届全球手术机器人大会 第二届全球医疗科技大会 2025 年 7 月 2 日 ， 医疗科技公司 Kardium 宣布 完成新一轮 2.5 亿美元 （约合人民币18亿）融资 ，为其用于 房颤治疗的创新产品—— Globe 脉冲场消融系统 （Globe PFA System）进入市场铺路。 新资金将用于支持 Globe 系统的 FDA 审批、产能扩建、商业化团队搭建，以及继续拓展产品在心律失常治疗 领域的临床研究。 "这笔资金让我们能够在全球范围内推进 Globe 系统的商业化。"Kardium 首席执行官 Kevin Chaplin 表示，"我 们的目标是将这项技术带给数百万房颤患者，改善他们的生活质量。" # 研发背景 房颤 是心律失常领域最为常见的疾病 ...

Core Viewpoint - The article highlights the rapid growth and potential of the pulse field ablation (PFA) market in China, driven by the increasing prevalence of atrial fibrillation (AF) and advancements in medical technology [5][8]. Group 1: Industry Background - Atrial fibrillation (AF) is the most common type of arrhythmia, characterized by rapid and irregular heartbeats, with a projected patient population of 22.67 million in China by 2025, growing at a compound annual growth rate (CAGR) of 2.85% from 2021 to 2025 [4]. - Traditional ablation methods, including radiofrequency and cryoablation, have significant complications, highlighting the need for safer and more effective solutions [4]. Group 2: Market Potential - The PFA market in China is expected to reach 1.3 billion yuan by 2025, with a CAGR of 43.73%, potentially growing to 16.3 billion yuan by 2032 [5]. - The share of PFA in the overall electrophysiology device market is projected to increase from 8.18% in 2025 to 38.87% in 2032 [5]. Group 3: Technological Advancements - The ALPHATRION® nanosecond pulse field ablation device utilizes a proprietary technology that outputs up to 2000V, offering higher tissue selectivity and reduced risks compared to traditional methods [9]. - The STARTREK™ three-dimensional dielectric imaging navigation system is the first of its kind in China, integrating imaging, mapping, navigation, and damage assessment [10][11]. Group 4: Clinical Developments - The first successful procedure using the integrated system for drug-resistant paroxysmal atrial fibrillation was completed in May 2024 [17]. - A clinical study presented at the HRS annual meeting in May 2024 demonstrated the feasibility and safety of the nanosecond PFA system [18][20]. Group 5: Competitive Landscape - Several domestic companies, including Jinjiang Electronics and Denovo Electrophysiology, have developed PFA systems, with Jinjiang's product being the first approved in December 2023 [24][26]. - The competitive landscape includes various players like Boston Scientific and Medtronic, which have also launched PFA systems with promising clinical outcomes [28][30][33]. Group 6: Company Overview - Jianhu Medical, founded in 2021, focuses on integrated solutions for cardiac electrophysiology, possessing both three-dimensional dielectric mapping technology and nanosecond pulse ablation technology [39].